Targeted therapies and radiotherapy in lung cancer] |
| |
| Authors: | C Hennequin |
| |
| Affiliation: | 1. Department of Radiation Oncology, University of Michigan, Ann Arbor Veterans Affairs Hospital, Ann Arbor, Michigan;2. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama;3. Department of Radiation Oncology, University of Colorado at Denver, Denver, Colorado;4. Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas;5. Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada;6. Radiation Oncology, SSM Cancer Care, St Louis, Missouri;7. Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California;8. Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan;1. Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, University of Calgary, Alberta, Canada;2. Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada |
| |
| Abstract: | ![]()
Targeted therapies are now more often used in lung cancer. Inhibitors of EGFR and of angiogenesis have demonstrated a certain activity in this disease. Some experimental in vitro or in vivo studies are in favour of combined targeted therapies and radiation. For example, additive or supra-additive effects have been shown when inhibitors of the EGFR tyrosine kinase were given with radiation. In advanced lung cancer, the combination of bevacizumab with chemotherapy was demonstrated to produce better survival outcomes. But a high rate of fatal hemoptysis was reported with this drug, particularly for central and squamous tumors. This could be a limitation for its use in combination with radiation. Drugs with multiple targets are becoming available; their association with radiation seems to be promising. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
